NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro

Circulation Research

Volumn 92, Issue 7, 2003, Pages 725-731

  Pu, William T ^a   Ma, Qing ^b   Izumo, Seigo ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Calcineurin; Cardiac hypertrophy; NFAT; Phenylephrine

Indexed keywords

CALCINEURIN; CYCLOSPORIN A; PEPTIDE; PHENYLEPHRINE; PROTEIN; PROTEIN VIVIT; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ASSAY; CELL CULTURE; CELL STIMULATION; CELL SURVIVAL; CELLULAR PARAMETERS; CONTROLLED STUDY; HEART MUSCLE CELL; HYPERTROPHY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AMINO ACID SEQUENCE; ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; CALCINEURIN; CELL SURVIVAL; CYCLOSPORINE; DNA-BINDING PROTEINS; GENE EXPRESSION; GREEN FLUORESCENT PROTEINS; HUMANS; IN SITU NICK-END LABELING; IONOMYCIN; JURKAT CELLS; LUMINESCENT PROTEINS; MOLECULAR SEQUENCE DATA; MYOCYTES, CARDIAC; NFATC TRANSCRIPTION FACTORS; NUCLEAR PROTEINS; OLIGOPEPTIDES; PHENYLEPHRINE; PROTEIN ISOFORMS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 0037453589     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000069211.82346.46     Document Type: Article

References (33)

1. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-228.
2. Wilkins BJ, Molkentin JD. Calcineurin and cardiac hypertrophy: where have we been? Where are we going? J Physiol. 2002;541:1-8.
3. Yang G, Meguro T, Hong C, Asai K, Takagi G, Karoor VL, Sadoshima J, Vatner DE, Bishop SP, Vatner SF. Cyclosporine reduces left ventricular mass with chronic aortic banding in mice, which could be due to apoptosis and fibrosis. J Mol Cell Cardiol. 2001;33:1505-1514.
4. Saito S, Hiroi Y, Zou Y, Aikawa R, Toko H, Shibasaki F, Yazaki Y, Nagai R, Komuro I. β-Adrenergic pathway induces apoptosis through calcineurin activation in cardiac myocytes. J Biol Chem. 2000;275:34528-34533.
5. Kakita T, Hasegawa K, Iwai-Kanai E, Adachi S, Morimoto T, Wada H, Kawamura T, Yanazume T, Sasayama S. Calcineurin pathway is required for endothelin-1-mediated protection against oxidant stress-induced apoptosis in cardiac myocytes. Circ Res. 2001;88:1239-1246.
6. De Windt LJ, Lim HW, Taigen T, Wencker D, Condorelli G, Dorn GW 2nd, Kitsis RN, Molkentin JD. Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: an apoptosis-independent model of dilated heart failure. Circ Res. 2000;86:255-263.
7. Oie E, Bjornerheim R, Clausen OP, Attramadal H. Cyclosporin A inhibits cardiac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats. Am J Physiol Heart Circ Physiol. 2000;278:H2115-H2123.
8. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol. 1997;15:707-747.
9. Ichida M, Finkel T. Ras regulates NFAT3 activity in cardiac myocytes. J Biol Chem. 2001;276:3524-3530.
10. Van Rootj E, Doevendans PA, De Theije CC, Babiker FA, Molkentin JD, De Windt LJ. Requirement of nuclear factor of activated T-cells (NFAT) in calcineurin mediated cardiomyocyte hypertrophy. J Biol Chem. 2002;277:48617-48626.
11. Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, Schroder F, Molkentin JD, Drexler H, Wollert KC. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A. 2002;99:11363-11368.
12. Wilkins BI, De Windt LJ, Bueno OF, Braz JC, Glascock BJ, Kimball TF, Molkentin JD. Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol Cell Biol. 2002;22:7603-7613.
13. Aramburu J, Yaffe MB, Lopez-Rodriguez C, Cantley LC, Hogan PG, Rao A. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science. 1999;285:2129-2133.
14. Sun LJ, Peterson BR, Verdine GL. Dual role of the nuclear factor of activated T cells insert region in DNA recognition and cooperative contacts to activator protein 1. Proc Natl Acad Sci USA. 1997;94:4919-4924.
15. Hedin KE, Bell MP, Kalli KR, Huntoon CJ, Sharp BM, McKean DJ. δ-Opioid receptors expressed by Jurkat T cells enhance IL-2 secretion by increasing AP-1 complexes and activity of the NF-AT/AP-1-binding promoter element. J Immunol. 1997;159:5431-5440.
16. Aoki H, Richmond M, Izumo S, Sadoshima J. Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro. Biochem J. 2000;347:275-284.
17. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J, Cantley LC, Izumo S. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 2000;19:2537-2548.
18. Khwaja A, Rodriguez-Viciana P, Wennstrom S, Warne PH. Downward J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J. 1997;16:2783-2793.
19. Taigen T, De Windt LJ, Lim HW, Molkentin JD. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A. 2000;97:1196-1201.
20. De Windt LJ, Lim HW, Bueno OF, Liang Q, Delling U, Braz JC, Glascock BJ, Kimball TF, del Monte F, Hajjar RJ, Molkentin JD. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2001;98:3322-3327.
21. Rothermel BA, McKinsey TA, Vega RB, Nicol RL, Mammen P, Yang J, Antos CL, Shelton JM, Bassel-Duby R, Olson EN, Williams RS. Myocyte-enriched calcineurin-interacting protein. MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci USA. 2001;98:3328-3333.
22. Zou Y, Hiroi Y. Uozumi H, Takimoto E, Toko H, Zhu W, Kudoh S, Mizukami M, Shimoyama M, Shibasaki F, Nagai R, Yazaki Y, Komuro I. Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. Circulation. 2001;104:97-101.
23. Adams JW, Pagel AL, Means CK, Oksenberg D, Armstrong RC, Brown JH. Cardiomyocyte apoptosis induced by Gαq signaling is mediated by permeability transition pore formation and activation of the mitochondrial death pathway. Circ Res. 2000;87:1180-1187.
24. Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB, Chien KR, Brown JH, Dorn GW 2nd. Enhanced Gαq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci U S A. 1998;95:10140-10145.
25. 2+-independent protein kinase C (nPKC) activation and its regulation by calcineurin activation. J Biol Chem. 1998;273:28392-28398.
26. 2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science. 1999;284:339-343.
27. Jayaraman T, Marks AR. Calcineurin is downstream of the inositol 1,4,5-trisphosphate receptor in the apoptotic and cell growth pathways. J Biol Chem. 2000;275:6417-6420.
28. Zhao Y, Tozawa Y, Iseki R, Mukai M, Iwata M. Calcineurin activation protects T cells from glucocorticoid-induced apoptosis. J Immunol. 1995;154:6346-6354.
29. Lotem J, Kama R, Sachs L. Suppression or induction of apoptosis by opposing pathways downstream from calcium-activated calcineurin. Proc Natl Acad Sci U S A. 1999;96:12016-12020.
30. 2+-dependent gene expression mediated by MEF2 transcription factors. J Biol Chem. 2000;275:197-209.
31. Yang TT, Xiong Q, Enslen H, Davis RJ, Chow CW. Phosphorylation of NFATc4 by p38 mitogen-activated protein kinases. Mol Cell Biol. 2002;22:3892-3904.
32. Gomez del Arco P, Martinez-Martinez S, Maldonado JL, Ortega-Perez I, Redondo JM. A role for the p38 MAP kinase pathway in the nuclear shuttling of NFATp. J Biol Chem. 2000;275:13872-13878.
33. Molkentin JD. Calcineurin and beyond: cardiac hypertrophic signaling. Circ Res. 2000;87:731-738.